The Prevalence of Initial Drug Resistance among Pulmonary Tuberculosis Patients

Background: Drug resistant tuberculosis (TB) in patients who have not received previous TB treatment (initial drug resistance) is a serious problem for the control of TB. However, prevalence of initial drug resistance among pulmonary TB patients has not been well characterized in Korea, especially in the private sector. We assessed the prevalence of initial drug resistance and evaluated the risk factors for drug resistance in pulmonary TB patients, at a regional tertiary hospital in Cheonan. Methods: We performed a drug susceptibility test for both first and second line anti-TB drugs in all culture-confirmed pulmonary TB patients who had not received a previous TB treatment at Dankook University Hospital from September 2005 to September 2007. In addition, we evaluated the initial drug resistance pattern and clinical characteristics of patients to evaluate the risk factors for initial drug resistance. We also assessed the influence of the drug susceptibility test results on the treatment regimen. Results: Of the total 156 cases where the drug susceptibility test was performed, resistance to at least one anti-TB drug was found in 21 cases (15.6%) and multidrug resistance, where TB was resistant to at least isoniazid and rifampin, was found in one case (0.6%). Multivariate logistic regression showed no clinical characteristics were independently associated with initial drug resistance. Of the total 156 patients who underwent the drug susceptibility test, the treatment regimen was changed for 15 patients (9.6%) according to the results of the drug susceptibility test. Conclusion: Initial drug resistance is common and the drug susceptibility test is informative for pulmonary TB patients who have not received previous TB treatment.

keywords: Drug resistance, Initial, Pulmonary tuberculosis

Reference

Hong Kong Tuberculosis Treatment Services/British Medical Research Council Investigation. A study in Hong Kong to evaluate the role of pretreatment susceptibility tests in the selection of regiments of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1972;106:1-22.

Korean Academy of Tuberculosis and Respiratory Diseases. Guideline for the management of pulmonary tuberculosis, 1997. Tuberc Respir Dis 1997;44:1447-53.

American Thoracic Society/Center for Disease Control and Prevention. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000;161:1376-95.

Korean Academy of Tuberculosis and Respiratory Diseases. Guideline for the management of pulmonary tuberculosis. Seoul: Korean Academy of Tuberculosis and Respiratory Diseases; 2005.

Bai GH. Anti-tuberculosis drug resistance in Korea. CDMR 2005;16:101-7.

Jung YJ, Park IN, Hong SB, Oh YM, Lim CM, Lee SD, et al. The clinical characteristics, diagnosis, treatment, and outcomes of patients with tuberculosis at a private university hospital in Korea. Tuberc Respir Dis 2006; 60:194-204.

Son CH, Yang DK, Rho MS, Jeong JS, Lee H, Lee KN, et al. Prevalence of drug-resistances in patients with pulmonary tuberculosis and its association with clinical characteristics at one tertiary referral hospital in Pusan, Korea. Tuberc Respir Dis 2001;51:416-25.

Jeong SH, Lee DD, Choi JC, Kim SJ, Shin JH, Jeong JS, et al. Multi-center study on cost effectiveness of anti-tuberculosis drug susceptibility test. Infect Chemother 2005;37:16-21.

Choi JC, Lim SY, Suh GY, Chung MP, Kim H, Kwon OJ, et al. Drug resistance rates of Mycobacterium tuberculosis at a private referral center in Korea. J Korean Med Sci 2007;22:677-81.

10.

National Tuberculosis Association of USA. Diagnostic standards and classification of tuberculosis. New York: National Tuberculosis Association; 1961.

11.

Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. N Engl J Med 1998;338:1641-9.

12.

Dye C, Espinal MA, Watt CJ, Mbiaga C, Williams BG. Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 2002;185:1197-202.

13.

Koh HK, Kang YJ, Lim SY, Shin JW, Choi JS, Yoo JH, et al. Predictors of drug-resistance in patients with pulmonary tuberculosis. Tuberc Respir Dis 1999;46:311-6.

14.

Min J, Park K, Whang S, Kim J. Risk factors for primary multidrug resistant tuberculosis. Tuber Respir Dis 2005; 59:600-5.

15.

Koziel H, Koziel MJ. Pulmonary complications of diabetes mellitus. Infect Dis Clin North Am 1995;9:65-96.

16.

Bashar M, Alcabes P, Rom WN, Condos R. Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997. Chest 2001;120:1514-9.

17.

Kim DK, Kim MO, Kim TH, Sohn JW, Yoon HJ, Shin DH, et al. The prevalence and risk factors of drug resistant pulmonary tuberculosis investigated at one university hospital in Seoul. Tuberc Respir Dis 2005; 58:243-7.

18.

Bass JB Jr, Farer LS, Hopewell PC, O'Brien R, Jacobs RF, Ruben F, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med 1994;149: 1359-74.

19.

American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62.

20.

Escalante P, Graviss EA, Griffith DE, Musser JM, Awe RJ. Treatment of isoniazid-resistant tuberculosis in southeastern Texas. Chest 2001;119:1730-6.

21.

Koh WJ, Kwon OJ, Yu CM, Jeon K, Kim KC, Lee BH, et al. Treatment of isoniazid-resistant pulmonary tuberculosis. Tuberc Respir Dis 2004;56:248-60.

바로가기메뉴

Article Contents

Vol.64 No.2

The Prevalence of Initial Drug Resistance among Pulmonary Tuberculosis Patients

Abstract

Reference

Tuberculosis & Respiratory Diseases